Theralink Technologies, Inc., based in Golden, CO, is a leading provider of innovative solutions in precision medicine for cancer therapy. Their advanced Theralink Assay utilizes protein biomarkers and signaling pathways to enable oncologists to make personalized treatment recommendations for cancer patients, revolutionizing the paradigm of cancer therapy. With over 600 protein and phosphoprotein targets evaluated through their RPPA technology, Theralink's services are supported by extensive scientific research and patents, making them a trusted partner for biotechnology and pharmaceutical companies in early and late-stage drug development.
By combining proteomic expression data with DNA sequencing, Theralink's assay provides valuable insights into the activation and driving factors of metastatic breast cancer growth, aiding oncologists like Dr. Joyce O'Shaughnessy in guiding therapy choices. The company's commitment to precision medicine and their cutting-edge technology has garnered praise from experts like Dr. Brian Leyland-Jones, who highlights the significant benefits of Theralink's assay in matching targeted therapies to patients. With a focus on advancing precision medicine, Theralink is poised to shape the future of cancer treatment.
Generated from the website